Portland Investment Counsel Inc. Invests $852,000 in Perspective Therapeutics, Inc. $CATX

Portland Investment Counsel Inc. acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 250,000 shares of the company’s stock, valued at approximately $852,000.

Several other large investors also recently added to or reduced their stakes in CATX. AXQ Capital LP grew its position in Perspective Therapeutics by 24.2% during the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after buying an additional 2,481 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Perspective Therapeutics by 6.1% in the 4th quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock valued at $149,000 after acquiring an additional 3,119 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in shares of Perspective Therapeutics by 25.0% in the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock valued at $69,000 after acquiring an additional 5,000 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after acquiring an additional 5,475 shares during the last quarter. Finally, Wealth Effects LLC boosted its position in shares of Perspective Therapeutics by 32.0% during the 1st quarter. Wealth Effects LLC now owns 33,000 shares of the company’s stock valued at $138,000 after acquiring an additional 8,000 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $3.30 on Monday. Perspective Therapeutics, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $6.16. The firm has a 50 day moving average price of $3.11 and a 200-day moving average price of $3.93.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.09 million. Equities analysts expect that Perspective Therapeutics, Inc. will post -1.03 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on CATX shares. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. BMO Capital Markets set a $11.00 price target on shares of Perspective Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Piper Sandler decreased their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Finally, Bank of America lowered their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $11.50.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.